CA2508226A1 — Novel heterocyclic fluoroglycoside derivatives, pharmaceutical products containing said compounds and the use thereof
Assigned to Sanofi Aventis Deutschland GmbH · Expires 2004-06-24 · 22y expired
What this patent protects
The invention relates to substituted fluoroglycoside heterocyclic derivative s of a formula (I), wherein radicals have predefined bonds, to the psychologically tolerated salts thereof and to methods for the preparation thereof. Said compounds can be used, for example as antidiabe…
USPTO Abstract
The invention relates to substituted fluoroglycoside heterocyclic derivative s of a formula (I), wherein radicals have predefined bonds, to the psychologically tolerated salts thereof and to methods for the preparation thereof. Said compounds can be used, for example as antidiabetic agents.</SD OAB>
Drugs covered by this patent
- Jardiance (empagliflozin) · Boehringer Ingelheim
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.